A slow-go prognosis for older patients with newly diagnosed AML

摘要

To determine which older patients may derive benefit from the prolonged pancytopenia and hospitalization associated with cytarabine-based induction chemotherapy, Itzykson et al, in this issue of Blood, report on a convenient clinical prognostic tool. The instrument, based on cytogenetic and molecular profiling, identifies which group of older and fit patients with newly diagnosed acute myeloid leukemia (AML) may derive survival benefit from intensive induction and consolidation chemotherapy.(1)